Clinical evaluation of a recombinant factor VIII preparation (Kogenate) in previously untreated patients with hemophilia A

The safety and efficacy of a recombinant factor VIII (rFVIII) preparation (Kogenate) for the treatment of bleeding episodes was studied in previously untreated patients (PUPs) with severe, moderate, and mild hemophilia A. Patient peripheral blood samples taken at baseline and at 3, 6, 9, 12, 18, and...

Ausführliche Beschreibung